Clinical Trials Browser

Completed × Surgical Procedures, Operative × 90 days × Clear all

Glioblastoma

NCT02676349 2026-03-27

Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)

Phase 2 Completed

130 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT06295809 2026-03-27

INTerpath-007

Phase 2/3 Completed

46 enrolled

Dermatologic

Carcinoma, Squamous Cell, Skin Neoplasms

NCT05577416 2026-03-18

AB-218-IIT-201

Phase EARLY_PHASE1 Completed

14 enrolled

CNS

Astrocytoma, Glioma, Oligodendroglioma

NCT01612351 2026-03-17

Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery

Phase 2 Completed

40 enrolled 20 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT00911911 2026-03-13

SPAM

Phase NA Completed

66 enrolled

Breast

Breast Neoplasms

NCT04024462 2026-02-20

A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

Phase 3 Completed

200 enrolled 16 charts

Breast

HER2-positive Early Breast Cancer

NCT05415215 2026-02-10

ProHer

Phase 3 Completed

346 enrolled 20 charts

Breast

Breast Neoplasms, Patient Preference, Inflammatory Breast Neoplasms

NCT04700124 2026-02-05

KEYNOTE-B15

Phase 3 Completed

808 enrolled

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

Clinical Trials

STEMRI

Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)

INTerpath-007

AB-218-IIT-201

Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery

SPAM

A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

ProHer

KEYNOTE-B15